España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Innoviva
INVA
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$17.84
-0.09
-0.50%
At close: -
$18.00
0.16
0.90%
After Hours: Dec 20, 4:02 PM EDT
Get Report
Comment
Innoviva (INVA) Forecast
News
Earnings
Innoviva (INVA) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Innoviva (NASDAQ:INVA) Stock
Innoviva Stock (NASDAQ: INVA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 16, 2024
Innoviva Specialty Therapeutics Enters Exclus...
Benzinga Newsdesk
Basilea Licenses U.S. Commercialization Right...
Benzinga Newsdesk
Thursday, August 01, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Wednesday, July 31, 2024
Innoviva Q2 EPS $(0.55) Misses $0.23 Estimate...
Benzinga Newsdesk
Tuesday, July 30, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Thursday, June 20, 2024
Cantor Fitzgerald Reiterates Overweight on In...
Benzinga Newsdesk
Tuesday, June 18, 2024
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Vandana Singh
Cantor Fitzgerald Initiates Coverage On Innov...
Benzinga Newsdesk
Monday, May 20, 2024
Zai Lab And Innoviva Specialty Therapeutics R...
Benzinga Newsdesk
Wednesday, May 08, 2024
Innoviva Q1 EPS $0.46 Beats $0.17 Estimate, S...
Benzinga Newsdesk
Wednesday, April 24, 2024
Innoviva Specialty Announced That Positive Re...
Benzinga Newsdesk
Friday, March 08, 2024
Insider Decision Unfolding At Innoviva: Pavel Raifeld Exercises Options
Benzinga Insights
Monday, March 04, 2024
Armata Pharmaceuticals Enters Secured Credit ...
Benzinga Newsdesk
5 Value Stocks In The Healthcare Sector
Benzinga Insights
Thursday, February 29, 2024
Innoviva Q4 EPS $0.76 Beats $0.23 Estimate, Sales $85.84M Beat $75.51M Estimate
Happy Mohamed
Wednesday, November 01, 2023
Innoviva Q3 EPS $0.98, Sales $67.26M Miss $75...
Benzinga Newsdesk
Innoviva Q3 EPS $0.98 May Not Compare To $0.2...
Benzinga Newsdesk
The Global Antibiotic Research & Development ...
Benzinga Newsdesk
Monday, October 02, 2023
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
Monday, September 18, 2023
XACDURO, The First And Only Antibiotic Develo...
Benzinga Newsdesk
Friday, September 01, 2023
Innoviva Chief Financial Officer Awarded $1.93M Worth of Stock Options
Benzinga Insights
Thursday, August 03, 2023
Chief Medical Officer at Innoviva Acquires Company Stock Options Worth 60,000 Shares
Benzinga Insights
Wednesday, August 02, 2023
CORRECTION: Innoviva Q2 EPS $0.02 Misses $0.26 Estimate, Sales $80.99M Beat $67.92M Estimate
Happy Mohamed
Innoviva Q2 EPS $0.02 Misses $0.26 Estimate, ...
Benzinga Newsdesk
Monday, July 31, 2023
Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights
Tuesday, July 11, 2023
Armata Pharmaceuticals Announces New Financing And Leadership Transition To Accelerate Novel Bacteriophage Therapeutics; Dr. Deborah L. Birx Appointed As Chief Executive Officer
Happy Mohamed
Wednesday, May 24, 2023
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
Vandana Singh
Tuesday, May 16, 2023
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
Lisa Levin
Monday, May 15, 2023
A Look Into Healthcare Sector Value Stocks
Benzinga Insights
Wednesday, May 10, 2023
EF Hutton Reiterates Buy on Innoviva, Maintai...
Benzinga Newsdesk
CORRECTION: Innoviva Q1 EPS $0.42 Beats $0.23 Estimate, Sales $76.37M Beat $61.46M Estimate
Happy Mohamed
Tuesday, May 09, 2023
Innoviva Q1 EPS $0.42 Beats $0.23 Estimate, Sales $76.37M Beat $61.46M Estimate
Happy Mohamed
Monday, May 08, 2023
5 Value Stocks In The Healthcare Sector
Benzinga Insights
Thursday, April 20, 2023
EF Hutton Reiterates Buy on Innoviva, Maintai...
Benzinga Newsdesk
Tuesday, April 18, 2023
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Vandana Singh
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
Vandana Singh
Monday, April 17, 2023
Innoviva Shares Resume Trade
Michael Horton
Innoviva Announces The FDA Voted In Support O...
Benzinga Newsdesk
Innoviva Stock Trading Halted Today; FDA Advisory Committee To Review Sulbactam-Durlobactam For The Treatment Of Hospital-Acquired And Ventilator-Associated Bacterial Pneumonia Caused By Susceptible Strains Of Acinetobacter
Happy Mohamed
Innoviva Shares Halted, News Pending
Happy Mohamed
Tuesday, March 14, 2023
Reported Late Monday March 13, Innoviva Announces FDA Advisory Committee Meeting To Review Sulbactam-Durlobactam An Investigational Targeted Antibiotic On April 17, 2023
Happy Mohamed
Friday, March 10, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Friday, March 03, 2023
What 4 Analyst Ratings Have To Say About Innoviva
Benzinga Insights
Goldman Sachs Maintains Neutral on Innoviva, ...
Benzinga Newsdesk
Morgan Stanley Maintains Underweight on Innov...
Benzinga Newsdesk
EF Hutton Reiterates Buy on Innoviva, Maintai...
Benzinga Newsdesk
Wednesday, March 01, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Tuesday, February 28, 2023
Innoviva Q4 EPS $(0.98) May Not Compare To $0...
Bill Haddad
Tuesday, January 24, 2023
Morgan Stanley Maintains Underweight on Innov...
Benzinga Newsdesk
Monday, December 19, 2022
Innoviva Earnings Perspective: Return On Capital Employed
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch